Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) is now available.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has established a Remuneration Committee to enhance its remuneration management system and optimize corporate governance. This committee is responsible for formulating appraisal standards and reviewing remuneration policies for directors and senior management, ensuring compliance with the Hong Kong Listing Rules. The move is expected to strengthen the company’s governance structure and provide transparent procedures for developing remuneration policies, which could positively impact its operations and stakeholder confidence.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and production of biopharmaceutical products. The company is involved in creating innovative healthcare solutions and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 703,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$71.59B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.